首页> 美国卫生研究院文献>Frontiers in Neurology >Endovascular Treatment of Intracranial Atherosclerotic Stenosis: Current Debates and Future Prospects
【2h】

Endovascular Treatment of Intracranial Atherosclerotic Stenosis: Current Debates and Future Prospects

机译:颅内动脉粥样硬化狭窄的血管内治疗:当前争论和未来前景。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Intracranial atherosclerotic stenosis (ICAS) is a common cause of transient ischemic attack (TIA) and ischemic stroke. Endovascular treatment, including balloon angioplasty alone, balloon-mounted stents, and self-expandable stent placement with or without prior angioplasty, is an alternative to medical treatment for the prevention of recurrent TIA or ischemic stroke in patients with ICAS. Although the SAMMPRIS and VISSIT trials supported medical management alone against endovascular treatments, both randomized controlled trials (RCT) were criticized due to flaws relating to patient-, intervention-, and operator-related factors. In this review, we discuss the current debate regarding these aspects and suggest approaches to solve current controversies in the future. In our opinion, endovascular treatment in carefully selected patients, individualized choice of endovascular treatment subtypes, and an experienced multidisciplinary team managing the patient in the pre-, peri- and post-procedural period have the potential to provide safe and efficious treatment of patients with symptomatic ICAS.
机译:颅内动脉粥样硬化狭窄(ICAS)是短暂性脑缺血发作(TIA)和缺血性中风的常见原因。血管内治疗,包括单独的球囊血管成形术,球囊安装式支架以及在有或没有事先血管成形术的情况下可自行扩张的支架置入术,是预防ICAS患者复发性TIA或缺血性中风的替代药物。尽管SAMMPRIS和VISSIT试验仅支持针对血管内治疗的医学管理,但由于与患者,干预和操作员相关因素有关的缺陷,两项随机对照试验(RCT)均受到批评。在这篇评论中,我们讨论了有关这些方面的当前辩论,并提出了解决未来争议的方法。我们认为,对精心选择的患者进行血管内治疗,对血管内治疗亚型进行个性化选择以及经验丰富的多学科团队在术前,围术中和术后均对患者进行治疗,有可能为患有以下疾病的患者提供安全有效的治疗有症状的ICAS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号